The CCND1 G870A Gene Polymorphism and Leukemia or Non-Hodgkin Lymphoma Risk: a Meta-analysis

  • Qin, Ling-Yan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Zhao, Li-Gang (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Chen, Xu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Yang, Zheng (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Mo, Wu-Ning (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
  • Published : 2014.08.30


In recent years, mounting evidence has indicated that the CCND1 G870A gene polymorphism, which impacts the mitotic cell cycle, may influence leukemia or non-Hodgkin lymphoma risk. Unfortunately, the previous results were inconsistent. Therefore, a meta-analysis was performed to obtain a more precise estimation of any association. We conducted a search in PubMed, Embase and CNKI covering all published papers up to March, 2014. A total of 9 publications including 10 case-control studies met the inclusion criteria. Odds ratios (ORs) and their 95% confidence intervals (95%CIs) were applied to assess association. The pooled ORs showed significant association in non-Hodgkin lymphoma (comparison A vs G: OR= 1.114, 95%CI=1.053-1.179, p=0.000; homozygote comparison AA vs GG: OR=1.245, 95%CI=1.110-1.396, p=0.000; heterozygote comparison AG vs GG: OR=1.095, 95%CI=1.000-1.199, p=0.05; dominant model AA/GA vs GG: OR=1.137, 95%CI=1.043-1.239, p=0.003; and recessive model AA vs GA/GG: OR=1.177, 95%CI=1.066-1.301, p=0.001). However, there was no association between the CCND1 G870A polymorphism and leukemia risk. In conclusion, the CCND1 G870A polymorphism may increase risk of non-Hodgkin lymphoma, but not leukemia. However, more primary large scale and well-designed studies are still required to evaluate the interaction of CCND1 G870A polymorphism with leukemia and non-Hodgkin lymphoma risk.


Leukemia;non-Hodgkin lymphoma;CCND1 gene;polymorphism;meta-analysis


  1. Advani AS, Hunger SP, Burnett AK (2009). Acute leukemia in adolescents and young adults. Semin Oncol, 36, 213-26.
  2. Akkiz H, Bayram S, Bekar A, Akgollu E, Ozdil B (2010). Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol, 34, 298-302.
  3. Bala S, Peltomaki P (2001). CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res, 61, 6042-5.
  4. Bassig BA, Lan Q, Rothman N, Zhang Y, Zheng T (2012). Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update. J Cancer Epidemiol, 2012, 978930.
  5. Bedewy AM, Mostafa MH, Saad AA, et al (2013). Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer. J BUON, 18, 227-38.
  6. Betticher DC, Thatcher N, Altermatt HJ, et al (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene, 11, 1005-11.
  7. Catarino R, Coelho A, Nogueira A, et al (2012). Cyclin D1 polymorphism in non-small cell lung cancer in a Portuguese population. Cancer Biomark, 12, 65-72.
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  9. Diehl JA (2002). Cycling to cancer with cyclin D1. Cancer Biol Ther, 1, 226-31.
  10. Donnellan R, Chetty R (1998). Cyclin D1 and human neoplasia. Mol Pathol, 51, 1-7.
  11. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  12. Evan GI, Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8.
  13. Fernberg P, Chang ET, Duvefelt K, et al (2010). Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control, 21, 759-69.
  14. Gijtenbeek JM, Boots-Sprenger SH, Franke B, Wesseling P, Jeuken JW (2005). Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol, 74, 261-6.
  15. Hou X, Wang S, Zhou Y, et al (2005). Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol, 82, 206-9.
  16. Howe D, Lynas C (2001). The cyclin D1 alternative transcripts (a) and (b) are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica, 86, 563-9.
  17. Li Y, Zhang S, Geng JX, et al (2012). Effects of the cyclin D1 polymorphism on lung cancer risk-a meta-analysis. Asian Pac J Cancer Prev, 13, 2325-8.
  18. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  19. Morton LM, Wang SS, Cozen W, et al (2008). Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood, 112, 5150-60.
  20. Morton LM, Purdue MP, Zheng T, et al (2009). Risk of non- Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev, 18, 1259-70.
  21. Qian PX, Wang L (2012). Correlation between Cyclin D1 gene polymorphism and acute lymphoblastic leukemia in children. Int J Laboratory Med, 33, 1567-8.
  22. Qiuling S, Yuxin Z, Suhua Z, et al (2003). Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis, 24, 1499-503.
  23. Rong LC, Xu HY, Rui YY, et al (2010). The association study between the CCND1 G870A polymorphism and risk of children with acute lymphoblastic leukemia. J Nanjing Med Univers, 30, 1700-2
  24. Sherr CJ (1995). D-type cyclins. Trends Biochem Sci, 20, 187-90.
  25. Solomon DA, Wang Y, Fox SR, et al (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 278, 30339-47.
  26. Stieglitz E, Loh ML (2013). Genetic predispositions to childhood leukemia. Ther Adv Hematol, 4, 270-90.
  27. Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 70-1.
  28. Tobias A, Campbell MJ (1999). Modelling influenza epidemics in the relation between black smoke and total mortality. A sensitivity analysis. J Epidemiol Community Health, 53, 583-4.
  29. Wang L, Habuchi T, Mitsumori K, et al (2003). Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer, 103, 116-20.
  30. Wang L, Wang Z, Gao X, et al (2014). Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis. Tumour Biol, 35, 1149-55.
  31. Wang SL, Hou JW, Song J, et al (2006). Approach on the polymorphism of cyclin D1 for chinese children patients with acute lymphoblastic leukemia. Chinese J Clinical Oncol, 33, 126-9.
  32. Wang SL, Zhang JB, Huang G, et al (2011). Study of Cyclin D1 gene polymorphism in chronic myelocytic leukemia. Jilin Med J, 32, 7221-4.
  33. Wang SS, Cozen W, Severson RK, et al (2006). Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum Genet, 120, 297-300.
  34. Yang Y, Wang F, Shi C, et al (2012). Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case-control studies. PLoS One, 7, 36813.
  35. Zeybek U, Yaylim I, Ozkan NE, et al (2013). Cyclin D1 gene G870A variants and primary brain tumors. Asian Pac J Cancer Prev, 14, 4101-6.

Cited by

  1. G870A (rs9344) polymorphism and cancer risk in Indian population: meta-analysis and trial sequential analysis vol.38, pp.6, 2018,